Anti‐nuclear antibodies in patients with breast cancer

• Published in: Clinical and experimental immunology 2018-08, Vol.193 (2), p.178-182
• Main Authors: Nisihara, R., Machoski, M. C. C., Neppel, A., Maestri, C. A., Messias‐Reason, I., Skare, T. L.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antibodies; Antibodies, Antinuclear - blood; Antigens, Nuclear - immunology; autoantibodies; autoimmunity; Benign; Biopsy; Brazil - epidemiology; Breast cancer; Breast Neoplasms - epidemiology; Breast Neoplasms - immunology; cancer; Carcinogenesis; Carcinoma, Ductal - epidemiology; Carcinoma, Ductal - immunology; Estrogens; Female; Humans; Image detection; Immunofluorescence; Lesions; Middle Aged; Neoplasm Staging; Neoplasms - epidemiology; Neoplasms - immunology; Original; Patients; Prevalence; Progesterone; Receptors, Estrogen - metabolism; Tumors
• ISSN: 0009-9104; 1365-2249
• DOI: 10.1111/cei.13136

Summary To study the prevalence of anti‐nuclear antibodies (ANA) in breast cancer patients and its association with tumour characteristics. Ninety‐one patients with breast mass detected by image studies and assigned to conduct diagnostic biopsy and eventual surgical treatment were studied for demographical, tumour data and presence of ANA. Serum of positive ANA patients was screened for the extractable nuclear antigen (ENA) profile. As comparison, 91 healthy individuals matched for age and from the same geographical area were included. In this sample 72 of 91 (79·1%) had malignant lesions (83% ductal infiltrative carcinoma). ANA was positive in 44·4% of patients with malignant tumour and in 15·7% of those with benign lesions (malignant versus benign with P = 0·03). Controls had ANA positivity in 5·4%, and when compared with tumour samples showed P